BridgeBio Pharma Total Long Term Liabilities 2018-2024 | BBIO
BridgeBio Pharma total long term liabilities from 2018 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
BridgeBio Pharma Annual Total Long Term Liabilities
(Millions of US $) |
| 2023 |
$1,746 |
| 2022 |
$1,745 |
| 2021 |
$1,745 |
| 2020 |
$502 |
| 2019 |
$98 |
| 2018 |
$55 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Total Long Term Liabilities
(Millions of US $) |
| 2024-09-30 |
$1,745 |
| 2024-06-30 |
$1,742 |
| 2024-03-31 |
$1,745 |
| 2023-12-31 |
$1,746 |
| 2023-09-30 |
$1,744 |
| 2023-06-30 |
$1,744 |
| 2023-03-31 |
$1,742 |
| 2022-12-31 |
$1,745 |
| 2022-09-30 |
$1,738 |
| 2022-06-30 |
$1,735 |
| 2022-03-31 |
$1,751 |
| 2021-12-31 |
$1,745 |
| 2021-09-30 |
$1,425 |
| 2021-06-30 |
$1,407 |
| 2021-03-31 |
$1,388 |
| 2020-12-31 |
$502 |
| 2020-09-30 |
$496 |
| 2020-06-30 |
$487 |
| 2020-03-31 |
$476 |
| 2019-12-31 |
$98 |
| 2019-09-30 |
$79 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
